Sensus Healthcare (NASDAQ:SRTS) Shares Cross Below 50 Day Moving Average - Should You Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report)'s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $5.63 and traded as low as $4.57. Sensus Healthcare shares last traded at $4.77, with a volume of 130,239 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SRTS shares. HC Wainwright upped their price target on shares of Sensus Healthcare from $11.00 to $12.00 and gave the company a "buy" rating in a report on Monday, February 10th. Lake Street Capital decreased their target price on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th.

Sensus Healthcare Trading Up 6.6 %

The firm's fifty day moving average price is $5.51 and its 200-day moving average price is $6.53. The company has a market cap of $82.97 million, a P/E ratio of 12.58 and a beta of 1.28.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, research analysts forecast that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in shares of Sensus Healthcare by 30.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock valued at $2,620,000 after buying an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Sensus Healthcare by 81.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock valued at $1,039,000 after purchasing an additional 67,269 shares in the last quarter. Marshall Wace LLP grew its stake in Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock worth $915,000 after buying an additional 65,994 shares during the last quarter. Millennium Management LLC grew its position in Sensus Healthcare by 256.6% during the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock worth $590,000 after acquiring an additional 61,403 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Sensus Healthcare during the 4th quarter valued at $381,000. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.